Evidence map›Paper›PMID 40622001›Full record

ArticleCancer reports (Hoboken, N.J.)2025

Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non-Small Cell Lung Cancer With ATM Mutation: A Case Report.

Zhiting Tang, Ran Bi, Mutasim Idriss, Qian Wang, Qi Wang, Makiko Ban-Hoefen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiting TangDepartment of Medicine, Unity Hospital, Rochester Regional Health, Rochester, New York, USA.ORCID 0009-0009-6479-3947
Ran BiDepartment of Internal Medicine, Inspira Medical Center Vineland, Vineland, New Jersey, USA.ORCID 0000-0002-2917-7198
Mutasim IdrissDepartment of Medicine, Unity Hospital, Rochester Regional Health, Rochester, New York, USA.ORCID 0009-0008-3622-2357
Qian WangDivision of Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-1201-865X
Qi WangDepartment of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0009-0008-2387-0179
Makiko Ban-HoefenDivision of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0009-0000-1714-8130

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtaxia telangiectasia mutated (ATM) mutations represent the most common homologous recombination deficiency (HRD) mutation in non-small cell lung cancer (NSCLC). However, their therapeutic role in NSCLC has not been established. CASE: Here, we present a case of a 91-year-old male with metastatic NSCLC who progressed on multiple lines of treatment. Next-generation sequencing revealed ATM mutations, leading to the initiation of olaparib, which successfully achieved remission over a two-year period.

conclusionThis case underscores the promising role of olaparib in treating NSCLC with HRD, particularly ATM mutations, highlighting the importance of molecular testing and targeted therapies.

Indexed as

Ataxia Telangiectasia Mutated ProteinsCarcinoma, Non-Small-Cell LungLung NeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsAged, 80 and overHumansMaleMutationNeoplasm StagingRemission InductionTreatment OutcomeAtaxia Telangiectasia Mutated ProteinsATM protein, humanolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsATM mutationhomologous recombination deficiencyNSCLColaparib

Identifiers

PMID40622001
PMCPMC12231064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.